Abbvie.com - Pharmaceutical Research & Development | AbbVie

Provided by Alexa ranking, abbvie.com has ranked N/A in N/A and 5,585,364 on the world. abbvie.com reaches roughly 553 users per day and delivers about 16,593 users each month. The domain abbvie.com uses a Commercial suffix and it's server(s) are located in N/A with the IP number 159.180.132.176 and it is a .com domain.

WebAbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.

List of domain same IP 159.180.132.176

Keywords on this domain

abbvie

abbvie stock price

abbvie stock

abbvie careers

abbvie patient assistance

abbvie login

abbvie assist

abbvie.com/pas

abbvie logo

abbvie pipeline

abbvie pharmaceuticals

abbvie stock dividend

abbvie investor relations

abbvie stock price today

abbvie wikipedia

abbvie aktie

abbvie puerto rico

abbvie eye care

abbvie deutschland

abbvie sas

abbvie italia

abbvie brasil

abbvie portugal

abbvie farmaceutica

abbvie cdso director linkedin

Search Results related to abbvie.com on Search Engine

  • Pharmaceutical Research & Development | AbbVie

    abbvie.com

    https://www.abbvie.com/

    WebAbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.

    DA: 58 PA: 70 MOZ Rank: 70

  • Patient Assistance | AbbVie

    abbvie.com

    https://www.abbvie.com/patients/patient-support/patient-assistance.html

    WebOur Patient Assistance Programs are intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need. In 2022, we assisted nearly 200,000 people. Applying to myAbbVie Assist is simple.

    DA: 25 PA: 35 MOZ Rank: 64

  • Products | AbbVie

    abbvie.com

    https://www.abbvie.com/patients/products.html

    WebNov 2, 2023 · employees turning possibilities into reality for people and patients. Our products are approved in individual countries for specific uses and the information provided is governed by local regulations. Product availability, name and indicated use may vary by country. Please contact your local AbbVie office to learn more about products available ...

    DA: 64 PA: 94 MOZ Rank: 88

  • AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/ABBV/

    WebFind the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.

    DA: 66 PA: 43 MOZ Rank: 36

  • AbbVie - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/AbbVie

    WebAbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.

    DA: 32 PA: 7 MOZ Rank: 13

  • Online Application Overview | AbbVie

    abbvie.com

    https://www.abbvie.com/patients/patient-support/patient-assistance/online-application-overview.html

    WebOur online application is for use by people over the age of eighteen and seeking assistance (the patient) for either HUMIRA ® (adalimumab), SKYRIZI ® (risankizumab-rzaa) RINVOQ ® (upadacitinib) or MAVYRET ® (glecaprevir/pibrentasvir). We will ask you to register and complete an application.

    DA: 40 PA: 61 MOZ Rank: 58

  • Patients | AbbVie - Pharmaceutical Research & Development

    abbvie.com

    https://www.abbvie.com/patients.html

    WebNov 2, 2023 · 200,000+. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work.

    DA: 8 PA: 19 MOZ Rank: 23

  • AbbVie to Acquire ImmunoGen, including its Flagship Cancer …

    abbvie.com

    https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio

    WebNov 30, 2023 · NORTH CHICAGO, Ill., and WALTHAM, Mass., Nov. 30, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug …

    DA: 65 PA: 92 MOZ Rank: 66

  • AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024

    abbvie.com

    https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen

    WebFeb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05 - $11.25.

    DA: 15 PA: 29 MOZ Rank: 80

  • Investor Overview | AbbVie

    abbvie.com

    https://investors.abbvie.com/

    WebAbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.

    DA: 33 PA: 90 MOZ Rank: 4

Alexa Rank

Alexa

GLOBAL RANK

5,585,364
Alexa

Alexa Reach

0.0000244161
Alexa

Page length

N/A
Alexa

Alexa Rank Country N/A

N/A
Alexa

Daily Unique Visitors

553
Alexa

Monthly Unique Visitors

16,593

Vistor via Country

Country lang
Country code
Total visitor

United States

US

3,549

Indonesia

ID

2,776

Taiwan

TW

903

United Kingdom

GB

801

Brazil

BR

725

Nigeria

NG

634

Egypt

EG

533

Hong Kong

HK

503

Canada

CA

503

Australia

AU

438

Philippines

PH

314

India

IN

305

Malaysia

MY

300

Spain

ES

249

Germany

DE

242

Mexico

MX

232

France

FR

219

Italy

IT

202

Turkey

TR

186

Iraq

IQ

169

Thailand

TH

166

Netherlands

NL

159

Israel

IL

158

Cambodia

km

131

Algeria

DZ

101

Ireland

IE

91

Romania

RO

88

Jordan

JO

81

Poland

PL

78

Ghana

GH

75

Argentina

AR

71

South Africa

ZA

65

Belgium

BE

58

Czechia

CZ

53

Ukraine

UA

50

Japan

JA

50

Morocco

MA

48

South Korea

KO

46

Lebanon

LB

45

Saudi Arabia

SA

43

Austria

AT

41

Hungary

HU

40

Sweden

SE

38

Singapore

SG

37

Pakistan

PK

35

Bangladesh

BD

33

Denmark

DK

32

Greece

GR

30

Alexa Traffic Graph

Alexa daily traffic trend graph
Alexa Statistics Graph for abbvie.com
Alexa daily pageviews (percent) graph
Alexa Statistics Graph for www.nahklick.de
Alexa daily pageviews per user graph
Alexa Statistics Graph for abbvie.com
Alexa time on site (in minutes) graph
Alexa Statistics Graph for www.nahklick.de
Alexa bounce rate (percent) graph
Alexa Statistics Graph for abbvie.com
Alexa search visits graph
Alexa Statistics Graph for abbvie.com

SEOquake Zone

Title Tips
Description Tips
Keywords Tips
Viewport Tips
Icon
UTF-8

Mini site formation by Alexa Rank

MOZ Rank

DA
33

PA
90

MOZ Rank
4

DNS Record

Host Type Class TTL Extra
abbvie.com A IN 3600 Ip: 159.180.132.176
abbvie.com SOA IN 21600 Mname: ns11.constellix.com
Rname: dns.constellix.com
Serial: 2015010416
Refresh: 43200
Retry: 3600
Expire: 1209600
Minimum-ttl: 180
abbvie.com NS IN 21600 Target: ns31.constellix.com
abbvie.com NS IN 21600 Target: ns41.constellix.net
abbvie.com NS IN 21600 Target: ns51.constellix.net
abbvie.com NS IN 21600 Target: ns61.constellix.net
abbvie.com NS IN 21600 Target: ns11.constellix.com
abbvie.com NS IN 21600 Target: ns21.constellix.com
abbvie.com MX IN 3600 Pri: 5
Target: mx1.hc3464-92.iphmx.com
abbvie.com MX IN 3600 Pri: 5
Target: mx2.hc3464-92.iphmx.com
abbvie.com TXT IN 3600 Txt: v=spf1 exists:%{i}._i.%{d}._d.espf.dmp.cisco.com include:%{d}.ff.spf-protect.dmp.cisco.com -all
Entries_0: v=spf1 exists:%{i}._i.%{d}._d.espf.dmp.cisco.com include:%{d}.ff.spf-protect.dmp.cisco.com -all
abbvie.com TXT IN 3600 Txt: amazonses:chGuzayLUK/ogao5Ua0JZmrsyqvidKho9Qv+/2fFdYk=
Entries_0: amazonses:chGuzayLUK/ogao5Ua0JZmrsyqvidKho9Qv+/2fFdYk=
abbvie.com TXT IN 3600 Txt: asv=ac54fa86dd8ec4f2ef5f03e044baf79d
Entries_0: asv=ac54fa86dd8ec4f2ef5f03e044baf79d
abbvie.com TXT IN 3600 Txt: 4C6k/kGlDrhQxCbDYrYCfNLImNzQOVhPOivN79ewQxi7APsEl/pq/xXYHlo8Y1Uxzwh3vzzitGDKV0jzT2jnPw==
Entries_0: 4C6k/kGlDrhQxCbDYrYCfNLImNzQOVhPOivN79ewQxi7APsEl/pq/xXYHlo8Y1Uxzwh3vzzitGDKV0jzT2jnPw==
abbvie.com TXT IN 3600 Txt: stripe-verification=50cc00e0655902d8f029d11dee3a6b25526883e9081bedebf097dafc605f023f
Entries_0: stripe-verification=50cc00e0655902d8f029d11dee3a6b25526883e9081bedebf097dafc605f023f
abbvie.com TXT IN 3600 Txt: atlassian-domain-verification=YdYnVOIu4xblzVrd15f7tw8/EsDXPskZantPPOqzPMXyWYMWFNg/A1N71GlFCQt/
Entries_0: atlassian-domain-verification=YdYnVOIu4xblzVrd15f7tw8/EsDXPskZantPPOqzPMXyWYMWFNg/A1N71GlFCQt/
abbvie.com TXT IN 3600 Txt: google-site-verification=y4d9BI04ITWijZ9QDmV8qvd1Sp3KF4FRr5fUgI66g7s
Entries_0: google-site-verification=y4d9BI04ITWijZ9QDmV8qvd1Sp3KF4FRr5fUgI66g7s
abbvie.com TXT IN 3600 Txt: google-site-verification=juqFj9t_POG9CA1Divoad7a6S1FkifS8TnjaP5vuB2Q
Entries_0: google-site-verification=juqFj9t_POG9CA1Divoad7a6S1FkifS8TnjaP5vuB2Q
abbvie.com TXT IN 3600 Txt: A0B2B85245
Entries_0: A0B2B85245
abbvie.com TXT IN 3600 Txt: adobe-idp-site-verification=c28a4333875b49fb1c8bdc1fc5bcaa8ab0f6c189de97f2308aee0dbae96c7e79
Entries_0: adobe-idp-site-verification=c28a4333875b49fb1c8bdc1fc5bcaa8ab0f6c189de97f2308aee0dbae96c7e79
abbvie.com TXT IN 3600 Txt: adobe-sign-verification=25a3a61b139f67505076058d353c6bf3
Entries_0: adobe-sign-verification=25a3a61b139f67505076058d353c6bf3
abbvie.com TXT IN 3600 Txt: adobe-sign-verification=94bd2c9b7025764336d4f751c4ff67aa
Entries_0: adobe-sign-verification=94bd2c9b7025764336d4f751c4ff67aa
abbvie.com TXT IN 3600 Txt: apple-domain-verification=jWEZkcRms8HWYeU1
Entries_0: apple-domain-verification=jWEZkcRms8HWYeU1
abbvie.com TXT IN 3600 Txt: atlassian-domain-verification=jYFr5Ubbph5ao+EmkgwO1HLJDbbZOMgimkVh4YPn9sMespyvN9nRLSAVitwtYV8n
Entries_0: atlassian-domain-verification=jYFr5Ubbph5ao+EmkgwO1HLJDbbZOMgimkVh4YPn9sMespyvN9nRLSAVitwtYV8n
abbvie.com TXT IN 3600 Txt: cisco-ci-domain-verification=79658cad24bb0bd072d5034840b3b6cf2a22ec3b4bb74f98bf7503e8e276ba50
Entries_0: cisco-ci-domain-verification=79658cad24bb0bd072d5034840b3b6cf2a22ec3b4bb74f98bf7503e8e276ba50
abbvie.com TXT IN 3600 Txt: cloudbees-domain-verification=ce1d76367c04d17e18d4b6cd8e47845952134847
Entries_0: cloudbees-domain-verification=ce1d76367c04d17e18d4b6cd8e47845952134847
abbvie.com TXT IN 3600 Txt: docker-verification=3bbd846d-c480-40d8-ab7b-6ebbcc18eb5d
Entries_0: docker-verification=3bbd846d-c480-40d8-ab7b-6ebbcc18eb5d
abbvie.com TXT IN 3600 Txt: flexera-domain-verification-recrjwsbtwsnsjhh
Entries_0: flexera-domain-verification-recrjwsbtwsnsjhh
abbvie.com TXT IN 3600 Txt: google-site-verification=8NRsARdclfm3Y1qW3LFjB1RrPGAkpAh61JzWT1FtoLQ
Entries_0: google-site-verification=8NRsARdclfm3Y1qW3LFjB1RrPGAkpAh61JzWT1FtoLQ
abbvie.com TXT IN 3600 Txt: google-site-verification=rW3kfY6uvaXdldC_GcvHuszf6PcQ_A71XCturpcs9B4
Entries_0: google-site-verification=rW3kfY6uvaXdldC_GcvHuszf6PcQ_A71XCturpcs9B4
abbvie.com TXT IN 3600 Txt: google-site-verification=zl52bDjnwm2CGi4_WrEnmaDsGtg6mPJstk5OknO92RU
Entries_0: google-site-verification=zl52bDjnwm2CGi4_WrEnmaDsGtg6mPJstk5OknO92RU
abbvie.com TXT IN 3600 Txt: h1-domain-verification=t9pgZRYpaEvJcc7TueKK3aZCuz8fd3mNDmPgmA9BDCWdVFzb
Entries_0: h1-domain-verification=t9pgZRYpaEvJcc7TueKK3aZCuz8fd3mNDmPgmA9BDCWdVFzb
abbvie.com TXT IN 3600 Txt: mongodb-site-verification=UAKSCPv6RQfqRXeMYsrSJ9AqMWOhBUo3
Entries_0: mongodb-site-verification=UAKSCPv6RQfqRXeMYsrSJ9AqMWOhBUo3
abbvie.com TXT IN 3600 Txt: onetrust-domain-verification=0e40a8dd990846d39323a0661cb8a7ef
Entries_0: onetrust-domain-verification=0e40a8dd990846d39323a0661cb8a7ef
abbvie.com TXT IN 3600 Txt: smartsheet-site-validation=TzfnpmDhd_kOj60YI7EJWU1dMNnb833w
Entries_0: smartsheet-site-validation=TzfnpmDhd_kOj60YI7EJWU1dMNnb833w
abbvie.com TXT IN 3600 Txt: smartsheet-site-validation=Wv0ZiQQYHu9pQJ5M_LhhUPmDX6Y0N23x
Entries_0: smartsheet-site-validation=Wv0ZiQQYHu9pQJ5M_LhhUPmDX6Y0N23x
abbvie.com TXT IN 3600 Txt: stripe-verification=17f64d574feba3451f201047b19eb818fdf3e72c52905ea729478ed219f3f165
Entries_0: stripe-verification=17f64d574feba3451f201047b19eb818fdf3e72c52905ea729478ed219f3f165
abbvie.com TXT IN 3600 Txt: stripe-verification=276d3f0450ac130211e5ea92f8cb880eefc236676c5048ba56075a71b0b24301
Entries_0: stripe-verification=276d3f0450ac130211e5ea92f8cb880eefc236676c5048ba56075a71b0b24301
abbvie.com TXT IN 3600 Txt: stripe-verification=b7766e752dd4a61c996b10b3dde39a4f445bc1322dbf4fcaea7c3374f88751ea
Entries_0: stripe-verification=b7766e752dd4a61c996b10b3dde39a4f445bc1322dbf4fcaea7c3374f88751ea
abbvie.com TXT IN 3600 Txt: webexdomainverification.275G2=f9995e66-3d81-4198-98c6-49af621378a4
Entries_0: webexdomainverification.275G2=f9995e66-3d81-4198-98c6-49af621378a4
abbvie.com TXT IN 3600 Txt: webexdomainverification.2IWS2=9fc3e43f-d12a-49a5-add6-523477a9ae3a
Entries_0: webexdomainverification.2IWS2=9fc3e43f-d12a-49a5-add6-523477a9ae3a
abbvie.com TXT IN 3600 Txt: webexdomainverification.4C675B8ADD6AB136E053AB06FC0A3F65=ad91b7fb-136a-4db4-a9bf-f2e90db03835
Entries_0: webexdomainverification.4C675B8ADD6AB136E053AB06FC0A3F65=ad91b7fb-136a-4db4-a9bf-f2e90db03835
abbvie.com TXT IN 3600 Txt: webexdomainverification.5c569c43d56deac6e053ab06fc0a4b3d=579f9f98-bfb1-4e6e-bf02-000646097c7b
Entries_0: webexdomainverification.5c569c43d56deac6e053ab06fc0a4b3d=579f9f98-bfb1-4e6e-bf02-000646097c7b
abbvie.com TXT IN 3600 Txt: webexdomainverification.F0XJ=7fd93f1e-7c4b-4fe1-9104-e0e6e8da4e68
Entries_0: webexdomainverification.F0XJ=7fd93f1e-7c4b-4fe1-9104-e0e6e8da4e68
abbvie.com TXT IN 3600 Txt: webexdomainverification.JUDP=9ff51131-bdcc-4443-a98b-bb4a9a3a7882
Entries_0: webexdomainverification.JUDP=9ff51131-bdcc-4443-a98b-bb4a9a3a7882
abbvie.com TXT IN 3600 Txt: ZOOM_verify_aqYKculqR_S-RdMwpmh36g
Entries_0: ZOOM_verify_aqYKculqR_S-RdMwpmh36g
abbvie.com TXT IN 3600 Txt: google-site-verification=SnTtb0xT-QRNowBgskJASiu_ptzfgov9ueJRo7aynsg
Entries_0: google-site-verification=SnTtb0xT-QRNowBgskJASiu_ptzfgov9ueJRo7aynsg
abbvie.com TXT IN 3600 Txt: google-site-verification=WxJAxiIPfh9iSDe7K9_mqeR8-oLtUDNyGEALop7PXLs
Entries_0: google-site-verification=WxJAxiIPfh9iSDe7K9_mqeR8-oLtUDNyGEALop7PXLs
abbvie.com TXT IN 3600 Txt: shopify-verification-code=1SspAjNbpItj9lYIbIAECfvgaNHaUe
Entries_0: shopify-verification-code=1SspAjNbpItj9lYIbIAECfvgaNHaUe
abbvie.com TXT IN 3600 Txt: mandrill_verify.oHZdlDYZNMJZmi75toEEqw
Entries_0: mandrill_verify.oHZdlDYZNMJZmi75toEEqw
abbvie.com TXT IN 3600 Txt: /zR4t2MmnLPO34NSA4Wg6wDuGkbWRbzEPnyjLF6rSSQ=
Entries_0: /zR4t2MmnLPO34NSA4Wg6wDuGkbWRbzEPnyjLF6rSSQ=
abbvie.com TXT IN 3600 Txt: miro-verification=bbe6162f677d9bda8ebacef01a21451f04f35f73
Entries_0: miro-verification=bbe6162f677d9bda8ebacef01a21451f04f35f73
abbvie.com TXT IN 3600 Txt: VI^#y1YzAigXZFrQ%UJ566IhWg56A0H#@C^A#!NLRQ&QBeydFM6J^Ot2R3UV%h9oBe!KqgZJ7R*HHfWQaViuVNLG%8$0#ZTYY6O
Entries_0: VI^#y1YzAigXZFrQ%UJ566IhWg56A0H#@C^A#!NLRQ&QBeydFM6J^Ot2R3UV%h9oBe!KqgZJ7R*HHfWQaViuVNLG%8$0#ZTYY6O
abbvie.com TXT IN 3600 Txt: loom-site-verification=374a3a55536948cab9374d69309c66cb
Entries_0: loom-site-verification=374a3a55536948cab9374d69309c66cb

Hosting and Whois Zone

IP 159.180.132.176
Domain infomation Domain Name: ABBVIE.COM
Registry Domain ID: 1704513840_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2024-01-27T09:43:35Z
Creation Date: 2012-02-28T17:01:26Z
Registry Expiry Date: 2025-02-28T17:01:26Z
Registrar: MarkMonitor Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2086851750
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Domain Status: serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited
Domain Status: serverTransferProhibited https://icann.org/epp#serverTransferProhibited
Domain Status: serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited
Name Server: NS11.CONSTELLIX.COM
Name Server: NS21.CONSTELLIX.COM
Name Server: NS31.CONSTELLIX.COM
Name Server: NS41.CONSTELLIX.NET
Name Server: NS51.CONSTELLIX.NET
Name Server: NS61.CONSTELLIX.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2024-04-18T21:43:54Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.